Condition category
Nutritional, Metabolic, Endocrine
Date applied
Date assigned
Last edited
Prospectively registered
Overall trial status
Recruitment status
No longer recruiting

Plain English Summary

Not provided at time of registration

Trial website

Contact information



Primary contact

Mrs Florence Day


Contact details

Clinical Trials Unit
B39 School of Community Health Sciences
Queens Medical Centre
Derby Road
United Kingdom

Additional identifiers

EudraCT number number

Protocol/serial number


Study information

Scientific title


DRN 819 Leucopatch II

Study hypothesis

Diabetic foot ulcers are the source of considerable suffering and cost and there are currently no wound care products available that have been demonstrated to improve healing, or that are cost effective. There have however been a small number of studies which have examined the use of platelets or fluid derived from platelets, either from the patients own blood or from blood bank products. These have suggested some promise, but have suffered from technical difficulties in making a suitable wound care product or the volume of blood required to derive the product. It is thought that the reason why they may work is that growth factors released by the platelets may stimulate the wound to heal.

This study will be a formal, randomised controlled trial to assess a new device for creating a wound care product which is a plug or patch comprising fibrin, white cells and platelets derived from 18 mls of the patients own blood. The application of this fibrin/white cell/platelet patch to the patients wound on a weekly basis will be compared with usual best care in patients with hard to heal Diabetic Foot Ulcers in a secondary care setting in 25 centres in the UK, Denmark and Sweden.

Ethics approval

13/WM/0202; First MREC approval date 24/05/2013

Study design

Randomised; Interventional; Design type: Treatment

Primary study design


Secondary study design

Randomised controlled trial

Trial setting


Trial type


Patient information sheet


Topic: Diabetes Research Network; Subtopic: Both; Disease: Diabetic foot


Leucopatch, topical application of a fibrin/white cell/platelet patch prepared by the Leucopatch device
Study Entry : Registration and One or More Randomisations

Intervention type



Phase IV

Drug names

Primary outcome measures

Ulcer healing; Timepoint(s): 20 weeks after randomisation

Secondary outcome measures

Not provided at time of registration

Overall trial start date


Overall trial end date


Reason abandoned


Participant inclusion criteria

1. People aged 18 years and over who have diabetes complicated by one or more ulcers on a foot or both feet below the level of the malleoli, excluding ulcers confined to the interdigital cleft
2. Those with more than one eligible ulcer will have one usually the largest or more clinically significant selected at screening as the index ulcer
3. Eligible ulcers will be hard-to-heal, meaning that the cross-sectional area will decrease by less than 50 % during a four week run-in period
4. HbA1c =108 mmol/mol at screening
5. The cross-sectional area of the index ulcer will be =50 and =1000 mm2 at the end of the 4 week run-in period
6. The index ulcer will be clinically non-infected according to IDSA criteria
7. Either the ankle-brachial index (ABPI) in the affected limb will be between 0.50 and 1.40 or the dorsalis pedis pulse and/or tibialis posterior pulse will be palpable
8. Participants will have the capacity to understand study procedures, and will be able to provided written informed consent
Target Gender: Male & Female ; Lower Age Limit 18 years

Participant type


Age group




Target number of participants

Planned Sample Size: 250; UK Sample Size: 150

Participant exclusion criteria

1. Haemoglobin concentration <105 g/L or 6.5 mmol/L at screening
2. Presence of sickle-cell anaemia, haemophilia, thrombocytopenia (<100x109/L) or other clinically significant blood dyscrasia
3. Known potential infectivity of blood products, including known HIV and hepatitis
4. Dialysis or an estimated GFR (based on cystatine C or serum creatinine) <20 ml/min/1.73m2
5. Increase in cross-sectional area of the index ulcer by =25% during the 4 week run-in period, or is either smaller than 50 mm2 or larger than 1000 mm2 at the end of that time
6. Revascularisation procedure in the affected limb planned, or undertaken within the 4 weeks prior to screening
7. Current treatment with cytotoxic drugs or with systemically administered glucocorticoids
8. Treatment of foot ulcers with growth factors, stem cells or equivalent preparation within the 8 weeks prior to screening
9. Likely inability to comply with the need for weekly visits because of planned activity
10. Participation in another interventional clinical foot ulcer-healing trial within the 4 weeks prior to screening
11. Prior enrolment in this trial
12. Judgement by the investigator that the patient does not have the capacity to understand the study procedures or provide written informed consent

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom

Trial participating centre

Clinical Trials Unit
United Kingdom

Sponsor information


Nottingham University Hospitals NHS Trust (UK)

Sponsor details

MRC Institute of Hearing Research Nottingham Clinical Section
Eye Ear Nose and Throat Centre
Queens Medical Centre
Derby Road
United Kingdom

Sponsor type

Hospital/treatment centre



Funder type


Funder name

Reapplix (Denmark)

Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes